The margin would benefit from improved price yields and a reduction in the cost of goods sold.
Shares in a2 Milk are expected to rally when the market opens at 10 am, on the back of a2 Milk's better than expected margins, Matt Goodson, managing director of Salt Funds, said.
"I would expect to see quite a sharp, postive reaction," he said. "The outlook comments were better than expectations."
The dual-listed company previously reported its June year earnings before interest, tax, depreciation and amortisation (ebitda) jumped by 46.1 per cent to $413.6m, driven by a 41.4 per cent lift in turnover to $1.31b.
READ MORE:
• A2 Milk shares fall as major Chinese competitor emerges
• Market set for 50 per cent lift in a2 Milk profit on big Wednesday
• A2 Milk shares rally after Mengniu-Bellamy's deal
A key measure for a2 Milk - its ebitda to sales margin - came to 31.7 per cent in the previous financial year.
The company's net profit after tax of came to $287.7 million in the year, up 47 per cent.
A2 Milk's shares peaked at $18.02 just before the release of the company's annual result in August but has since dropped back to close yesterday at $12.66.
The company commercialises intellectual property relating to A1 protein-free milk that is sold under the a2 and a2 MILK brands, as well as the milk and related products like infant formula.
For the first half of the financial year, a2 Milk anticipates revenue in the range of $780m to $800m.
China label infant nutrition sales forecast to be about $135m, representing a
growth rate of about 84 per cent.
China cross border e-commerce formula sales are forecast to reach $155m, representing a growth rate of about 54 per cent.
Australia-New Zealand English label infant nutrition sales forecast to be about $350m, representing a growth rate of about 9 per cent.
In a separate statement, a2 Milk said it had extended its supply agreement with its part-owned supplier, Canterbury-based Synlait Milk.
The 2018 agreement provided for a minimum term of five years, with a rolling three-year term from August 1, 2020.
The key components of the revised agreement are:
• A two-year extension to the term of the agreement, effectively providing for a new minimum term to, at the earliest, July 31, 2025.
• An increase in the volume of nutritional products over which Synlait already has exclusive supply rights
• Increased committed production capacity from Synlait.